

Autor(id): Helena Lepassar

Küsimus:

Kontekst:

Bibliograafia:

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	intensiivne	tavapärase HbA1c eesmärkväärtuseid	Suhteline (95% CI)	Absoluutne (95% CI)		

Seerumi kreatiniinitaseme kahekordne tõus

4 <sup>1,2,3,4,a</sup>	randomiseeritud uuringud	väike	suur <sup>b</sup>	väike	väike	puudub	2890/14559 (19.9%)	2792/13030 (21.4%)	šansside suhe (OR) 0.98 (0.81 kuni 1.19)	3 vähem / 1,000 (33 vähem kuni 31 rohkem)	⊕⊕⊕○ KESKMINE	KRIITILINE
------------------------	--------------------------	-------	-------------------	-------	-------	--------	--------------------	--------------------	--	--	------------------	------------

Dialüüsi vajadus

4 <sup>1,2,3,4,a</sup>	randomiseeritud uuringud	väike	väike	väike	väike	puudub	194/14643 (1.3%)	218/13117 (1.7%)	šansside suhe (OR) 0.84 (0.69 kuni 1.02)	3 vähem / 1,000 (5 vähem kuni 0 vähem)	⊕⊕⊕⊕ KÕRGE	KRIITILINE
------------------------	--------------------------	-------	-------	-------	-------	--------	------------------	------------------	--	---	---------------	------------

Suremus (neerupuudulikkuse tõttu)

2 <sup>2,4,a</sup>	randomiseeritud uuringud	väike	väike	väike	väike	puudub	32/8642 (0.4%)	43/7118 (0.6%)	šansside suhe (OR) 0.62 (0.39 kuni 0.98)	2 vähem / 1,000 (4 vähem kuni 0 vähem)	⊕⊕⊕⊕ KÕRGE	KRIITILINE
--------------------	--------------------------	-------	-------	-------	-------	--------	----------------	----------------	--	---	---------------	------------

Alajäseme amputatsiooni risk

7 <sup>3,4,5,6,7,8,9,c</sup>	randomiseeritud uuringud	väike	väike	väike	väike	puudub	59/6552 (0.9%)	59/4345 (1.4%)	suhteline risk (RR) 0.65 (0.45 kuni 0.94)	5 vähem / 1,000 (7 vähem kuni 1 vähem)	⊕⊕⊕⊕ KÕRGE	KRIITILINE
------------------------------	--------------------------	-------	-------	-------	-------	--------	----------------	----------------	---	---	---------------	------------

Alajäsemete neuropaatia

2 <sup>3,6,c</sup>	randomiseeritud uuringud	väike	väike	väike	väike	puudub	199/972 (20.5%)	225/979 (23.0%)	suhteline risk (RR) 0.89 (0.75 kuni 1.05)	25 vähem / 1,000 (57 vähem kuni 11 rohkem)	⊕⊕⊕⊕ KÕRGE	KRIITILINE
--------------------	--------------------------	-------	-------	-------	-------	--------	-----------------	-----------------	---	---	---------------	------------

Isheemilised muutused alajäsemetes

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	intensiivne	tavapärase HbA1c eesmärkväärtuseid	Suhteline (95% CI)	Absoluutne (95% CI)		
4 <sup>4,5,6,9,c</sup>	randomiseeritud uuringud	väike	väike	väike	väike	puudub	67/3430 (2.0%)	62/1506 (4.1%)	<b>suhteline risk (RR) 0.92</b> (0.67 kuni 1.26)	<b>3 vähem / 1,000</b> ( 14 vähem kuni 11 rohkem)	⊕⊕⊕⊕ KÕRGE	KRIITILINE

CI: usaldusintervall; OR: šansimäär; RR: riskimäär

## Selgitused

a. Herrera-Gómez F, Asensio-González M, González-López A, Álvarez FJ. Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis. *Front Pharmacol.* 2017 Nov 21;8:845. doi: 10.3389/fphar.2017.00845. PMID: 29209216; PMCID: PMC5702491.

b. I2 = 50%

c. Hasan R, Firwana B, Elriyah T, Domecq JP, Prutsky G, Nabhan M, Prokop LJ, Henke P, Tsapas A, Montori VM, Murad MH. A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. *J Vasc Surg.* 2016 Feb;63(2 Suppl):22S-28S.e1-2. doi: 10.1016/j.jvs.2015.10.005. PMID: 26804364.

## Viited

1. Ismail-Beigi, Faramarz, Craven, Timothy, Banerji, Mary Ann, Basile, Jan, Calles, Jorge, Cohen, Robert M., Cuddihy, Robert, Cushman, William C., Genuth, Saul, Grimm, Richard H., Hamilton, Bruce P., Hoogwerf, Byron, Karl, Diane, Katz, Lois, Krikorian, Armand, O'Connor, Patrick, Pop-Busui, Rodica, Schubart, Ulrich, Simmons, Debra, Taylor, Harris, Thomas, Abraham, Weiss, Daniel, Hramiak, Irene, group, ACCORD,trial. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet* (London, England); Aug 07, 2010.
2. Group, ADVANCE,Collaborative, Patel, Anushka, MacMahon, Stephen, Chalmers, John, Neal, Bruce, Billot, Laurent, Woodward, Mark, Marre, Michel, Cooper, Mark, Glasziou, Paul, Grobbee, Diederick, Hamet, Pavel, Harrap, Stephen, Heller, Simon, Liu, Lisheng, Mancina, Giuseppe, Mogensen, Carl Erik, Pan, Changyu, Poulter, Neil, Rodgers, Anthony, Williams, Bryan, Bompont, Severine, de Galan, Bastiaan E., Joshi, Rohina, Travert, Florence. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *The New England Journal of Medicine*; Jun 12, 2008.
3. Duckworth, William, Abraira, Carlos, Moritz, Thomas, Reda, Domenic, Emanuele, Nicholas, Reaven, Peter D., Zieve, Franklin J., Marks, Jennifer, Davis, Stephen N., Hayward, Rodney, Warren, Stuart R., Goldman, Steven, McCarren, Madeline, Vitek, Mary Ellen, Henderson, William G., Huang, Grant D., Investigators, VADT. Glucose control and vascular complications in veterans with type 2 diabetes. *The New England Journal of Medicine*; Jan 08, 2009.
4. . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* (London, England); Sep 12, 1998.
5. Abraira, C., Colwell, J., Nuttall, F., Sawin, C. T., Henderson, W., Comstock, J. P., Emanuele, N. V., Levin, S. R., Pacold, I., Lee, H. S.. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. *Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Archives of Internal Medicine*; Jan 27, 1997.
6. Gaede, Peter, Lund-Andersen, Henrik, Parving, Hans-Henrik, Pedersen, Oluf. Effect of a multifactorial intervention on mortality in type 2 diabetes. *The New England Journal of Medicine*; Feb 07, 2008.
7. Araki, Atsushi, Iimuro, Satoshi, Sakurai, Takashi, Umegaki, Hiroyuki, Iijima, Katsuya, Nakano, Hiroshi, Oba, Kenzo, Yokono, Koichi, Sone, Hirohito, Yamada, Nobuhiro, Ako, Junya, Kozaki, Koichi, Miura, Hisayuki, Kashiwagi, Atsunori, Kikkawa, Ryuichi, Yoshimura, Yukio, Nakano, Tadasumi, Ohashi, Yasuo, Ito, Hideki, Group, Japanese,Elderly,Diabetes,Intervention,Trial,Study. Long-term multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial--study design, baseline characteristics and effects of intervention. *Geriatrics & Gerontology International*; Apr 2012.
8. Griffin, Simon J., Borch-Johnsen, Knut, Davies, Melanie J., Khunti, Kamlesh, Rutten, Guy E. H. M., Sandbæk, Anneli, Sharp, Stephen J., Simmons, Rebecca K., van den Donk, Maureen, Wareham, Nicholas J., Lauritzen, Torsten. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. *Lancet* (London, England); Jul 09, 2011.
9. Knatterud, G. L., Klimt, C. R., Levin, M. E., Jacobson, M. E., Goldner, M. G.. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. *JAMA*; Jul 07, 1978.